Replies to post #52090 on Biotech Values

[rfj1862]

>One would think a superior product on both safety and efficacy endpoints woudl capture even more than JAV's numbers, which are based on a 20-35% market share<

In the current environment, even more important is the ability to bolus dose. Pharmacoeconomic analyses indicate about a 50 pound stirling savings associated with bolus dosing over infusion. That's huge, and well worth the extra $7 (or about 3.50 stirling) per vial.

[rfj1862]

JAV

Another pretty huge advantage is the fact that Dyloject is stable at room temperature and does not require the intermediate step of pharmacy mixing before administration.

Intravenous infusions of Voltarol have to be freshly made up and used immediately. Once prepared, the infusion should not be stored.

In practice, what happens with these kinds of drugs is the pharmacy makes up N bags in the morning based on anticipated usage. Those that are not used are tossed at the end of the day. So you've just wasted the pharmacy time and the drug if it's not used.

Plus would you rather take the very expensive bed time and personnel cost to infuse, or would you rather administer the drug in a quick 30-second bolus?

If you were a hospital administrator, would you rather have a drug that needs to be mixed by the pharmacy and tossed at the end of the day, or would you rather just pop 20 vials of Dyloject in the Pyxis and forget about them until they're needed?

It's pretty clear that Voltarol is a dead duck when Dyloject is approved. It's also clear that a premium can be demanded for this drug--probably even more than they're anticipating.